EGFR and breast carcinoma: Tamoxifen has been shown to act as a GPER agonist, and GPER has been implicated in tamoxifen resistance via its upregulation in a tamoxifen resistant breast cancer cell line which results in the activation of epidermal growth factor receptor (EGFR) [12].